NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.

Cover of LiverTox

LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].

Show details


Last Update: October 8, 2015.



Vigabatrin is a GABA derivative that is used in combination with other agents as therapy of refractory complex partial seizures and as monotherapy for infantile spasms. Vigabatrin is associated with a paradoxical decrease in serum enzyme levels during therapy, explained by its direct inhibition of aminotransferase activity. Vigabatrin has not been convincingly linked to cases of clinically apparent liver injury, but was linked to a fatal case of Reye syndrome in a child with severe developmental delay.


Vigabatrin (vye ga' ba trin) is a vinyl derivative of gamma-aminobutyric acid (GABA) that acts as a competitive inhibitor of GABA transaminase. Vigabatrin prevents the breakdown of GABA and thus may increase GABAergic, neuroinhibitory activity. Vigabatrin has been shown to be effective in reducing seizure activity as add on therapy in patients with refractory partial onset seizures. It has been available in other countries for more than a decade, but was first approved for use in the United States in 2009. Current indications include as adjuvant therapy in patients with refractory complex partial seizures and as monotherapy for infantile spasms in children ages 1 month to 2 years. Vigabatrin is available in tablets of 500 mg and as a powder for oral solution under the brand name Sabril. The typical initial dose is 500 mg twice daily, with subsequent increases to a recommended average dose of 3000 mg daily in adults and 2000 mg in children 10 to 16 years of age. Side effects may include fatigue, somnolence, nystagmus, tremor, blurred vision, memory impairment, mood changes, confusion and weight gain. Rare, but severe adverse events include visual loss, visual field constriction and retinal dysfunction, for which reason vigabatrin is available only through a restricted program that requires prospective ophthalmologic monitoring.


In controlled clinical trials, addition of vigabatrin to standard anticonvulsant therapy was reported to cause an immediate and marked decrease in serum enzyme levels that could be reproduced by simply mixing vigabatrin with plasma. In some instances, markedly raised serum ALT levels were found to rapidly fall into the normal range with treatment. Vigabatrin inhibits GABA transaminase and is thus suspected of also being an inhibitor of alanine and aspartate aminotransferase, accounting for its unusual effects on liver associated enzymes. In prelicensure clinical trials, there were no reports of serum enzyme elevations during treatment and no instances of clinically apparent liver injury. After its general availability, however, there have been isolated case reports of severe liver injury and hepatitis associated with vigabatrin use. The onset of injury was 3 to 10 months after starting vigabatrin and was largely hepatocellular. One case resulted in rapid death from liver failure and a second worsened despite stopping and ultimately required a course of immunosuppression with prednisone and azathioprine. Thus, clinically apparent liver injury from vigabatrin may occur and can be severe, but is rare.

Likelihood score: D (possible rare cause of clinically apparent liver injury).

Mechanism of Injury

Vigabatrin is an amino acid derivative and is metabolized by many tissues in the body. It is unlikely to be directly hepatotoxic and is not reported to cause drug-drug interactions. Instances of liver injury from vigabatrin are likely to be due to hypersensitivity.

Outcome and Management

Patients who have developed serious hypersensitivity reactions to aromatic anticonvulsants such as phenytoin, carbamazepine and lamotrigine have later tolerated therapy with vigabatrin without recurrence. The structure of vigabatrin would suggest that it does not share sensitivity to other anticonvulsant agents.

Drug Class: Anticonvulsants


Case 1. Acute hepatitis attributed to vigabatrin.

[Modified from: Locher C, Zafrani ES, Dhumeaux D, Mallat A. [Vigabatrin-induced cytolytic hepatitis]. Gastroenterol Clin Biol 2001; 25: 556-7. French. PubMed Citation].

A 25 year old woman was found to have abnormal liver tests 10 months after starting vigabatrin for partial onset seizures. The serum bilirubin was minimally raised (2.0 mg/dL), but ALT values were 10 times and AST 8 times the upper limit of normal (Table). Vigabatrin was continued, but several weeks later she developed symptoms of fatigue and nausea and repeat blood testing showed persistence of the liver test abnormalities. Vigabatrin was stopped and she was referred for further evaluation. She denied a history of liver disease, alcohol abuse or risk factors for viral hepatitis. She was not taking other medications and denied use of over-the-counter drugs or herbal supplements. Physical examination was unremarkable and showed no fever or rash. Tests for acute hepatitis A, B and C were negative as were tests for EBV and CMV infection. Autoantibodies were not detected. Imaging of the liver by ultrasound was normal. A liver biopsy showed panlobular hepatitis with hepatocellular necrosis and inflammatory infiltrates of lymphocytes and eosinophils. Plasma cells and neutrophils were not prominent and there was no fat or fibrosis. Despite stopping vigabatrin, she continued to worsen and serum bilirubin rose to 4.1 mg/dL and prothrombin index fell to 54%. Because of the worsening and the possibility of autoimmune liver injury, prednisone and azathioprine were started, but blood tests had already showed evidence of improvement. Thereafter, she improved rapidly, and she was asymptomatic and all tests were normal one month later. The immunosuppressive therapy was gradually tapered and was stopped after 4 months. In follow up 8 months later, all liver tests remained normal.

Key Points

Pattern:Hepatocellular (R ratio=6.6)
Severity:Moderate (jaundice and hospitalization)
Latency:10 months
Recovery:2 months (with prednisone and azathioprine therapy)
Other medications:None

Laboratory Values

Time After StartingTime After StoppingALT* (U/L)Alk P (U/L)Bilirubin* (mg/dL)Other
7 months0350.6On therapy
10 months04002.0
10.5 months04401252.4Vigabatrin stopped
1 week16804.1
11 months2 weeks12003.0Prednisone started
3 weeks6402.2
1 month451.3
1 year2 months350.7
4 months300.6Prednisone stopped
2 years1 year300.5Asymptomatic
Normal Values<40<125<1.2

*Estimated from Figure 1 and converted to IU based upon default normal values.


A woman with partial onset seizures developed evidence of acute hepatitis 10 months after starting vigabatrin. She was taking no other medications and had no risk factors for viral hepatitis. Medical evaluation revealed no evidence for other forms of liver disease, and a liver biopsy was compatible with drug induced liver injury. Because of concerns over the severity of the injury and the possibility of an early autoimmune hepatitis, prednisone and azathioprine were started, but blood tests showed evidence of improvement even before these medications was started. In follow up, she was able to stop the immunosuppressive regimen without recurrence of injury, strong evidence against autoimmune hepatitis. This was a fairly convincing case of vigabatrin induced liver injury. The absence of other reports may merely reflect the fact that the drug is rarely used, particularly as monotherapy. Vigabatrin is approved in the United States, only as adjunctive therapy to be used with other anticonvulsant agents. Why a simple GABA derivative would cause liver toxicity is unclear. Despite the absence of signs of hypersensitivity, the most likely explanation is immunologic.



Vigabatrin – Sabril®




Product labeling at DailyMed, National Library of Medicine, NIH


Vigabatrin chemical structure
GABA (Gamma-Aminobutyric Acid)56-12-2C4-H9-N-O2
GABA chemical structure


References updated: 08 October 2015

  • Kaplowitz Zimmerman HJ. Anticonvulsants. In, Zimmerman, HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999: pp. 498-516.
    (Expert review of anticonvulsants and liver injury published in 1999 before the availability of vigabatrin).
  • Pirmohamed M, Leeder SJ. Anticonvulsant agents. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013: pp 423-42.
    (Review of anticonvulsant induced liver injury; vigabatrin is not discussed).
  • McNamara JO. Vigabatrin. Pharmacotherapy of the epilepsies. In, Brunton LL, Chabner BA, Knollman BC, eds. Goodman & Gilman’s the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011, p. 603.
    (Textbook of pharmacology and therapeutics).
  • Remy C, Beaumont D. Efficacy and safety of vigabatrin in the long-term treatment of refractory epilepsy. Br J Clin Pharmacol 1989; 27 Suppl 1: 125S-129S. [PMC free article: PMC1379691] [PubMed: 2757903]
    (Among 254 patients with refractory seizures treated with vigabatrin for an average of 23 months, “there was some alterations in liver transaminases” including a 30-50% decrease in ALT).
  • Ben-Menachem E, Persson L, Mumford J. Long-term evaluation of once daily vigabatrin in drug-resistant partial epilepsy. Epilepsy Res 1990; 5: 240-6. [PubMed: 2116964]
    (Among 35 patients with refractory partial onset seizures treated with adjunctive vigabatrin for up to 3 years, there were no changes in routine chemistry laboratory tests “that were considered to be clinically significant”).
  • Browne TR, Mattson RH, Penry JK, Smith DB, Treiman DM, Wilder BJ, Ben-Menachem E, et al. Multicenter long-term safety and efficacy study of vigabatrin for refractory complex partial seizures: an update. Neurology 1991; 41: 363-4. [PubMed: 2006001]
    (Among 66 patients with refractory seizures who received vigabatrin as add on therapy for 5 to 72 months, there were no abnormalities in laboratory studies).
  • Tartara A, Manni R, Galimberti CA, Morini R, Mumford JP, Iudice A, Perucca E. Six-year follow-up study on the efficacy and safety of vigabatrin in patients with epilepsy. Acta Neurol Scand 1992; 86: 247-51. [PubMed: 1414241]
    (Among 25 patients with partial onset seizures with a favorable response to adjunctive vigabatrin therapy and who were continued on treatment for 2-6 years, “there were no significant changes in standard…blood chemistry…tests” and no serious adverse events or need for discontinuation due to liver injury).
  • Cocito L, Maffini M, Loeb C. Vigabatrin in chronic epilepsy: a 7-year follow-up study of responder patients. Seizure 1993; 2: 301-7. [PubMed: 8162400]
    (Among 35 adults with epilepsy treated with vigabatrin as add on therapy for refractory epilepsy, 23 were continued on drug in an extension study, among whom there were “no significant effects” on any of the routine laboratory tests).
  • Williams A, Goldsmith R, Coakley J. Profound suppression of plasma alanine aminotransferase activity in children taking vigabatrin. Aust N Z J Med 1994; 4: 65. [PubMed: 8002862]
    (Among 12 children [ages 2 to 17 years] with poorly controlled seizures who were treated with vigabatrin, serum ALT levels decrease in all 12, from 13-72 U/L to 0-26 U/L, perhaps due to inhibition of alanine and aspartate as well as GABA transaminase).
  • Kellermann K, Soditt V, Rambeck B, Klinge O. Fatal hepatotoxicity in a child treated with vigabatrin. Acta Neurol Scand 1996; 93: 380-1. [PubMed: 8800351]
    (3 year old boy with developmental delay and seizures treated with phenobarbital developed fever and coma 3 months after the addition of vigabatrin [bilirubin not given, AST 54 rising to 577 U/L, ammonia 214 μmol/L] and progressive coagulopathy leading to death in 3 days, autopsy showing massive necrosis without fat, although mitochondrial changes suggested Reye syndrome).
  • Williams A, Sekaninova S, Coakley J. Suppression of elevated alanine aminotransferase activity in liver disease by vigabatrin. J Paediatr Child Health 1998; 34: 395-7. [PubMed: 9727187]
    (In a 16 month old boy with Alpers syndrome, severe developmental delay and liver disease, addition of vigabatrin to standard anticonvulsant therapy was followed by day 15 by a 91% decrease in ALT [247 to 18 U/L] and 19% decrease in Alk P levels [into the normal range], effects that could be reproduced in vitro, by addition of vigabatrin to plasma).
  • Bruni J, Guberman A, Vachon L, Desforges C. Vigabatrin as add-on therapy for adult complex partial seizures: a double-blind, placebo-controlled multicentre study. The Canadian Vigabatrin Study Group. Seizure 2000; 9: 224-32. [PubMed: 10777431]
    (Among 111 patients with refractory partial onset seizures who were treated with vigabatrin or placebo for 36 weeks, there were “no clinically significant abnormalities” of laboratory test results).
  • Guberman A, Bruni J. Long-term open multicentre, add-on trial of vigabatrin in adult resistant partial epilepsy. The Canadian Vigabatrin Study Group. Seizure 2000; 9: 112-8. [PubMed: 10845734]
    (Among 97 patients with refractory partial onset seizures who had completed participation in a placebo controlled trial and were continued on vigabatrin for up to 1 year, there were marked reductions in serum ALT, and no patient had a liver related serious adverse event or had to discontinue therapy because of liver injury).
  • Locher C, Zafrani ES, Dhumeaux D, Mallat A. [Vigabatrin-induced cytolytic hepatitis]. Gastroenterol Clin Biol 2001; 25: 556-7. French. [PubMed: 11521114]
    (25 year old woman with partial onset seizures developed acute hepatitis 10 months after starting vigabatrin [bilirubin 2.0 rising to 4.1 mg/dL, ALT 10 rising to 45 times ULN, Alk P 1.5 times ULN), ultimately treated with prednisone and azathioprine and improving rapidly, but able to stop all immunosuppression several months later without relapse: Case 1).
  • Galindo PA, Borja J, Gómez E, Mur P, Gudín M, García R, Encinas C, et al. Anticonvulsant drug hypersensitivity. J Investig Allergol Clin Immunol 2002; 12: 299-304. [PubMed: 12926190]
    (Among 15 patients with cutaneous hypersensitivity reactions to anticonvulsants [9 accompanied by liver test elevations] which were caused by carbamazepine [n=8], phenytoin [5], lamotrigine [4], phenobarbital [4], valproate [1] and felbamate [1], two patients later tolerated vigabatrin without recurrence).
  • Björnsson E. Hepatotoxicity associated with antiepileptic drugs. Acta Neurol Scan 2008; 118: 281-90. [PubMed: 18341684]
    (Review of the hepatotoxicity of anticonvulsants; no discussion of vigabatrin).
  • Camposano SE, Major P, Halpern E, Thiele EA. Vigabatrin in the treatment of childhood epilepsy: a retrospective chart review of efficacy and safety profile. Epilepsia 2008; 49: 1186-91. [PubMed: 18479386]
    (Among 84 children treated with vigabatrin for infantile spasms or partial onset seizures or both, side effects were uncommon and usually mild, leading to discontinuation in only 3 children, all 3 for psychiatric symptoms).
  • Vigabatrin (Sabril) for epilepsy. Med Lett Drugs Ther 2010; 52 (1332): 14-6. [PubMed: 20208475]
    (Concise summary of mechanism of action, clinical efficacy, adverse events and costs of vigabatrin shortly after its approval for use in the US mentions the serious adverse events of retinal dysfunction, intramyelinic edema and suicidal ideation as well as the common adverse events of anticonvulsants such as headache, fatigue, pain, ataxia, dizziness, somnolence, weight gain, depression and alterations in behavior, mood and thinking; no mention of ALT elevations or hepatotoxicity).
  • Walker SD, Kälviäinen R. Non-vision adverse events with vigabatrin therapy. Acta Neurol Scand Suppl 2011; (192): 72-82. [PubMed: 22061182]
    (Review of the common adverse events of vigabatrin therapy does not mention ALT elevations or hepatotoxicity).
  • Gaitatzis A, Sander JW. The long-term safety of antiepileptic drugs. CNS Drugs 2013; 27: 435-55. [PubMed: 23673774]
    (Review of the long term safety and adverse event profile of anticonvulsants mentions that valproate and felbamate can cause liver failure, but does not mention hepatotoxicity of other anticonvulsants).
  • Drugs for epilepsy. Treat Guidel Med Lett 2013; 11: 9-18. [PubMed: 23348233]
    (Concise review of indications and side effects of anticonvulsants; vigabatrin is approved as add on therapy of Lennox-Gastaut syndrome in children and adults; discussion of adverse effects does not mention hepatotoxicity, but mentions that vigabatrin is a mild inducer of CYP 3A4).
  • Björnsson ES, Bergmann OM, Björnsson HK, Kvaran RB, Olafsson S. Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013; 144: 1419-25. [PubMed: 23419359]
    (In a population based study of drug induced liver injury from Iceland, 96 cases were identified over a 2 year period, but of the 96, none were attributed to vigabatrin).
  • Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al.; United States Drug Induced Liver Injury Network. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. Gastroenterology 2015; 148: 1340-52. [PMC free article: PMC4446235] [PubMed: 25754159]
    (Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, 40 [4.5%] were attributed to anticonvulsants, but none to vigabatrin).


Related information

Similar articles in PubMed

See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...